The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
Abstract
Purpose: Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction. Patients and Methods: Patients with pathologically proven IIIA(N2) and selected patients with IIIB disease that had medical/functional operability received induction chemotherapy, which consisted of three cycles of cisplatin 50 mg/m 2 on days 1 and 8 and paclitaxel 175 mg/m 2 on day 1 every 21 days, as well as concurrent chemoradiotherapy to 45 Gy given as 1.5 Gy twice daily, concurrent cisplatin 50 mg/m 2 on days 2 and 9, and concurrent vinorelbine 20 mg/m 2 on days 2 and 9. Those patients whose tumors were reevaluated and deemed resectable in the last week of radiotherapy were randomly assigned to receive a chemoradiotherapy boost that was risk adapted to between 65 and 71 Gy in arm A or to undergo surgery (arm B). The primary end point was overall survival (OS). Results: After 246 of 500 planned patients were enrolled, the trial was closed after the second scheduled interim analysis because of slow accrual and the end of funding, which left the study underpowered relative to its primary study end point. Seventy-five patients had stage IIIA disease and 171 had stage IIIB disease according to the Union for International Cancer Control TNM classification, sixth edition. The median age was 59 years (range, 33 to 74 years). After induction, 161 (65.4%) of 246 patients with resectable tumors were randomly assigned; strata were tumor-node group, prophylactic cranial irradiation policy, and region. Patient characteristics were balanced between arms, in which 81 were assigned to surgery and 80 were assigned to a chemoradiotherapy boost. In arm B, 81% underwent R0 resection. With a median follow-up after random assignment of 78 months, 5-year OS and progression-free survival (PFS) did not differ between arms. Results were OS rates of 44% for arm B and 40% for arm A (log-rank P = .34) and PFS rates of 32% for arm B and 35% for arm A (log-rank P = .75). OS at 5 years was 34.1% (95% CI, 27.6% to 40.8%) in all 246 patients, and 216 patients (87.8%) received definitive local treatment. Conclusion: The 5-year OS and PFS rates in randomly assigned patients with resectable stage III non–small-cell lung cancer were excellent with both treatments. Both are acceptable strategies for this good-prognosis group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495
Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., Feins, R. H., Gandara, D. R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60737-6 · Cited by 1,470
Curran, W. J., Paulus, R., Langer, C. J., Komaki, R., Lee, J. S., Hauser, S., Movsas, B., Wasserman, T., Rosenthal, S. A., Gore, E., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr325 · Cited by 1,233
Cited by
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00276 · Cited by 333
Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly, M. E., Singh, N., Ismaila, N., Antonoff, M. B., Arenberg, D. A., Bradley, J., David, E., Detterbeck, F., Früh, M., Gubens, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02528 · Cited by 283
Metadata
- Authors
- Eberhardt, W. E. E., Pöttgen, C., Gauler, T. C., Friedel, G., Veit, S., Heinrich, V., Welter, S., Budach, W., Spengler, W., Kimmich, M., Fischer, B., Schmidberger, H., De Ruysscher, D., Belka, C., Cordes, S., Hepp, R., Lütke-Brintrup, D., Lehmann, N., Schuler, M., Jöckel, K.-H., Stamatis, G., & Stuschke, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-12-10
- Volume
- 33
- Issue
- 35
- Pages
- 4194-4201
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133223019
- Cited by
- 365
- References
- 22
- FWCI
- 24.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). https://app.cochat.ai/papers/10.1200/jco.2015.62.6812
- The paper
- Eberhardt, W. E. E., Pöttgen, C., Gauler, T. C., Friedel, G., Veit, S., Heinrich, V., Welter, S., Budach, W., Spengler, W., Kimmich, M., Fischer, B., Schmidberger, H., De Ruysscher, D., Belka, C., Cordes, S., Hepp, R., Lütke-Brintrup, D., Lehmann, N., Schuler, M., . . . Stuschke, M. (2015). Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.62.6812
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.